SCHEMBL1683376

SCHEMBL1683376

COc1cc2oc(-c3ccc(O)cc3)c(OC)c(=O)c2c(O)c1O

nearest known ligand 0.86

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.86
ABCG2 Q9UNQ0 1/20 0.86
POLB P06746 3/20 0.69
KDM4E B2RXH2 2/20 0.69
CYP3A4 P08684 2/20 0.69
CYP2D6 P10635 2/20 0.69
APEX1 P27695 1/20 0.69
RECQL P46063 1/20 0.69
MCL1 Q07820 1/20 0.69
POLH Q9Y253 1/20 0.69
MAPT P10636 3/20 0.67
MEN1 O00255 1/20 0.67
KMT2A Q03164 1/20 0.67
TUBB4A P04350 5/20 0.63
TUBB P07437 5/20 0.63
TUBA3C P0DPH7 5/20 0.63
TUBA1B P68363 5/20 0.63
TUBA4A P68366 5/20 0.63
TUBB4B P68371 5/20 0.63
TUBB3 Q13509 5/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Penduletin SCHEMBL30823992 0.92 ABCB1 (1.00) ABCB1ABCG2POLBKDM4ECYP3A4
Penduletin SCHEMBL2217068 0.92 ABCB1 (1.00) ABCB1ABCG2POLBKDM4ECYP3A4
SCHEMBL1683355 0.91 TUBB4A (0.76) ABCB1ABCG2POLBCYP3A4CYP2D6
SCHEMBL29598018 0.91 TUBB4A (0.76) ABCB1ABCG2POLBCYP3A4CYP2D6
SCHEMBL28095527 0.90 ABCG2 (0.70) ABCB1ABCG2POLBMAPTMEN1
SCHEMBL2727281 0.88 ABCG2 (0.83) ABCB1ABCG2POLBKDM4ECYP3A4
Chrysosplenol C SCHEMBL4742072 0.88 ABCG2 (0.73) ABCB1ABCG2POLBMAPTMEN1
SCHEMBL2928366 0.88 XDH (0.78) ABCB1ABCG2POLBKDM4EAPEX1
SCHEMBL1664156 0.86 ABCG2 (0.76) ABCB1ABCG2POLBKDM4ECYP3A4
3,6-Dimethoxy Kaempferol SCHEMBL30707828 0.86 TUBB4A (0.83) ABCB1ABCG2POLBKDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1698325-B1 Compositions containing amines and use thereof JOHNSON & JOHNSON CONSUMER (US) 2016-07-20 EP disclosed
US-8834943-B2 Compositions containing amines and use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2014-09-16 US disclosed
US-8278359-B2 Compositions containing amines and use thereof to treat acne or reduce the appearance of oil or pores on the skin JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2012-10-02 US disclosed
EP-2054046-B1 COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF JOHNSON & JOHNSON CONSUMER (US) 2012-09-26 EP disclosed
US-8221046-B2 Compositions containing amines and use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2012-07-17 US disclosed
US-8163313-B2 Compositions containing amines and use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2012-04-24 US disclosed
US-20110091586-A1 COMPOSITIONS CONTAINING AMINES AND USE THEREOF KENVUE BRANDS LLC 2011-04-21 US disclosed
EP-2248526-A1 Compositions containing an extract of asparagus and use thereof Johnson & Johnson Consumer Companies, Inc. (US) 2010-11-10 EP disclosed
US-20100279987-A1 COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF SALIOU CLAUDE 2010-11-04 US disclosed
US-7781410-B2 Compositions containing chalcones and use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2010-08-24 US disclosed
US-20050238612-A1 Gingko containing formulations for the improvement of skin radiance JOHNSON & JOHNSON CONSUMER FRANCE S.A.S. (FR) 2005-10-27 US disclosed
EP-1543822-A1 Soy containing formulations for the improvement of skin radiance Johnson & Johnson Consumer France SAS (FR) 2005-06-22 EP disclosed
EP-1543823-A1 Gingko containing formulations for the improvement of skin radiance Johnson & Johnson Consumer France SAS (FR) 2005-06-22 EP disclosed
EP-1100516-B1 EXTRACTS OF FEVERFEW (TANACETUM PARTHENIUM) AGAINST INFLAMMATORY DISORDERS JOHNSON & JOHNSON CONSUMER FR (FR) 2005-03-23 EP disclosed
WO-2004112819-A1 COMPOSITIONS AND METHODS OF TREATMENT COMPRISING PLANT EXTRACTS GELSTAT CORPORATION (US) 2004-12-29 WO disclosed
US-20040105905-A1 Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium) CALLAGHAN THERESA (NL) 2004-06-03 US disclosed
US-20030077343-A1 Composition containing feverfew extract and use thereof JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2003-04-24 US disclosed
US-20030003170-A1 Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium) CALLAGHAN THERESA (NL) 2003-01-02 US disclosed
US-20020182166-A1 Composition containing feverfew extract and use thereof CHENANGO ZERO LLC 2002-12-05 US disclosed
US-6410062-B1 Method for the topical treatment and prevention of inflammatory disorders and related conditions using extracts of feverfew (Tanacetum parthenium) JOHNSON & JOHNSON CONSUMER FRANCE SAS I3540 (FR) 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110091586-A1 COMPOSITIONS CONTAINING AMINES AND USE THEREOF H1-0, HRH3, C5 ABCB1 3097/4885ABCG2 1465/4885POLB 2353/4885
US-20100279987-A1 COMPOSITIONS CONTAINING CHALCONES AND USE THEREOF CYP17A1, HSD17B7, CUTA ABCB1 470/4885ABCG2 937/4885POLB 1221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.